Back
#1
23.1%
#1
9.3%
Top 2%
6.7%
Top 74%
6.2%
Top 42%
6.2%
Top 7%
5.2%
Top 0.5%
4.3%
Top 2%
2.9%
Top 36%
2.0%
Top 5%
1.6%
Top 13%
1.4%
Top 1%
1.4%
Top 9%
1.0%
Top 7%
1.0%
Top 8%
0.7%
Top 6%
0.7%
Top 2%
0.7%
Top 4%
0.7%
Top 10%
0.7%
Top 12%
0.7%
Efficacy of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma and Mutated or Deleted TP53
2024-12-02
hematology
Title + abstract only
View on medRxiv
Show abstract
BackgroundPatients with relapsed/refractory multiple myeloma (RRMM) and high-risk genetic abnormalities such as del(17p) and TP53 mutation have poor response to standard therapies and shorter survival compared to patients without these aberrations. Here, we investigated the activity and mechanism of action of peptide-drug conjugate melphalan flufenamide (melflufen) in TP53 wild type (TP53wt) and mutant (TP53mut) myeloma models and assessed the efficacy of melflufen in patients with del(17p) and/...
Predicted journal destinations
1
Blood Advances
16 training papers
2
Clinical Cancer Research
22 training papers
3
Frontiers in Immunology
140 training papers
4
PLOS ONE
1737 training papers
5
Scientific Reports
701 training papers
6
eLife
262 training papers
7
Journal of Clinical Investigation
50 training papers
8
JCI Insight
63 training papers
9
Nature Communications
483 training papers
10
Frontiers in Oncology
34 training papers
11
Frontiers in Medicine
99 training papers
12
Science Advances
52 training papers
13
iScience
74 training papers
14
Cancers
57 training papers
15
The American Journal of Human Genetics
77 training papers
16
Cell Reports Medicine
49 training papers
17
Cell
28 training papers
18
Science Translational Medicine
40 training papers
19
Nature Genetics
72 training papers
20
eBioMedicine
82 training papers